The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Paclitaxel plus bevacizumab with or without atezolizumab for hormone receptor-positive/HER2-negative advanced breast cancer: JCOG1919E (AMBITION) phase III trial.
 
Fumikata Hara
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Kyowa Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Kan Yonemori
Honoraria - Asterias Biotherapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Genmab; Gilead Sciences; Lilly Japan; Merck KGaA; MSD Oncology; Novartis; Ono Pharmaceutical; PDRadiopharma; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; EP biopharma; GlaxoSmithKline; Haihe Pharmaceutical; Henlius; Lilly Japan; MSD; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Makiko Ono
Speakers' Bureau - Chugai Pharma; Lilly Japan
Research Funding - Astellas Pharma (Inst); Eisai (Inst); Pfizer
 
Takayuki Ueno
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Guardant Health; Lilly Japan; Nipro Corporation; Pfizer
Research Funding - Lilly Japan (Inst)
 
Haruru Kotani
No Relationships to Disclose
 
Toshinari Yamashita
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Kyowa Hakko Kirin; Lilly; MSD; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Yakuhin (Inst); Pfizer (Inst); Seagen (Inst)
 
Takahiro Nakayama
Honoraria - AstraZeneca; Celltrion; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Pfizer; Sandoz; Sysmex
 
Shinsuke Sasada
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin International; Lilly Japan
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); Lilly Japan (Inst)
 
Hiroko Bando
Honoraria - Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Lilly Japan; MSD; Pfizer
 
Yuko Takahashi
Research Funding - MSD (Inst)
 
Kenichi Watanabe
No Relationships to Disclose
 
Minoru Miyashita
Honoraria - AstraZeneca; Chugai Foundation for Innovative Drug Discovery Science; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; MSD; Pfizer
 
Hiroyuki Yasojima
No Relationships to Disclose
 
Shin Takayama
Consulting or Advisory Role - Intuitive Surgical
 
Shigehisa Kitano
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Janssen; Kyowa Kirin International; Lilly Japan; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; GlaxoSmithKline; ImmuniT Research Inc.; Kyowa Kirin; Ono Pharmaceutical; Rakuten Medical; Sumitomo Dainippon Pharma; United Immunity
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kyowa Kirin (Inst); Lilly (Inst); Loxo/Lilly (Inst); Medpace (Inst); Merck KGaA (Inst); Moderna Therapeutics (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst); Takara Bio (Inst); Takeda (Inst)
 
Keita Sasaki
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - AstraZeneca; Otsuka; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shigehira Saji
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Gilead Sciences; Kyowa Kirin; Lilly; MSD; Myriad Genetics; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Kirin; Lilly; MSD; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Gilead Sciences; Lilly Japan; MSD; Myriad Genetics; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; CMIC Co., Ltd.; Daiichi Sankyo; Gilead Sciences; Lilly Japan; MSD; Pfizer
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst)